Verve Therapeutics, Inc.
Verve Therapeutics, Inc.（VERV）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · VERV · 截至 2026年6月9日
活动摘要
买入笔数
1
P-Purchase only
卖出笔数
8
近12个月
买卖比
0.13
Buy/Sell (by trades)
整体情绪
Verve Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
VERV 季度内部人买卖趋势
VERV 内幕交易卖出 · VERV 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · VERV CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
VERV 高管卖出股份 · VERV 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jul 25, 2025 | GV 2017 GP, L.L.C. 10 percent owner | Other | 1,800,000 | $18.90M⚡ | Form 4 |
| Jul 25, 2025 | Yeshwant Krishna Director | Other | 1,800,000 | $18.90M⚡ | Form 4 |
| Jul 25, 2025 | Dorval Allison CFO | Other | 13,280 | $139K | Form 4 |
| Jul 25, 2025 | Nickerson Joan Chief Administrative Officer | Other | 17,420 | $183K | Form 4 |
| Jul 25, 2025 | Kathiresan Sekar CEO · Director | Other | 240,997 | $2.53M⚡ | Form 4 |
| Jul 25, 2025 | Lister Troy Chief Scientific Officer | Other | 6,952 | $73K | Form 4 |
| Jul 25, 2025 | ADELMAN BURT A Director | Other | 428,326 | $4.50M⚡ | Form 4 |
| Jul 25, 2025 | Ashe Andrew D. See Remarks | Other | 348,828 | $3.66M⚡ | Form 4 |
| Jul 25, 2025 | Politi Jason Chief Technical Ops. Off. | Other | 16,405 | $172K | Form 4 |
| Apr 1, 2025 | Kathiresan Sekar CEO · Director | Option | 33,000 | — | Form 4 |
| Apr 2, 2025 | Kathiresan Sekar CEO · Director | Sale | 9,822 | $41K | Form 4 |
| Apr 1, 2025 | Nickerson Joan Chief Administrative Officer | Option | 9,315 | — | Form 4 |
| Apr 2, 2025 | Nickerson Joan Chief Administrative Officer | Sale | 2,777 | $12K | Form 4 |
| Apr 1, 2025 | Ashe Andrew D. See Remarks | Option | 9,000 | — | Form 4 |
| Apr 2, 2025 | Ashe Andrew D. See Remarks | Sale | 2,681 | $11K | Form 4 |
| Apr 1, 2025 | Politi Jason Chief Technical Ops. Off. | Option | 8,815 | — | Form 4 |
| Apr 2, 2025 | Politi Jason Chief Technical Ops. Off. | Sale | 3,235 | $13K | Form 4 |
| Apr 1, 2025 | Dorval Allison CFO | Option | 11,250 | — | Form 4 |
| Apr 2, 2025 | Dorval Allison CFO | Sale | 3,350 | $14K | Form 4 |
| Apr 1, 2025 | Lister Troy Chief Scientific Officer | Option | 7,340 | — | Form 4 |
| Apr 2, 2025 | Lister Troy Chief Scientific Officer | Sale | 2,189 | $9K | Form 4 |
| Dec 4, 2024 | Kathiresan Sekar CEO · Director | Gift | 30,000 | — | Form 4 |
| Dec 4, 2024 | Kathiresan Sekar CEO · Director | Gift | 30,000 | — | Form 4 |
GV 2017 GP, L.L.C.
10 percent owner
日期
Jul 25
股数
1,800,000
均价
$10.50
总金额
$18.90M ⚡
Nickerson Joan
Chief Administrative Officer
日期
Jul 25
股数
17,420
均价
$10.50
总金额
$183K
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 VERV 内幕交易
VERV 内幕交易
Verve Therapeutics, Inc.（VERV）内幕交易数据来源于公司内部人（包括GV 2017 GP, L.L.C. (10 percent owner), Yeshwant Krishna (Director), Dorval Allison (CFO)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。VERV内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Verve Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
VERV 内幕交易 · 5个问题Verve Therapeutics, Inc.（VERV）的内部人包括高管和董事，如GV 2017 GP, L.L.C. (10 percent owner), Yeshwant Krishna (Director), Dorval Allison (CFO)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026